Therapeutic Antibodies in Stroke

• Main Authors: Yu, C.Y, Ng, G, Liao, P
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Review
• Published: 2020
• Subjects: adalimumab; alpha amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid; CD18 antibody; CD18 antigen; endothelial leukocyte adhesion molecule 1; endothelial leukocyte adhesion molecule 1 antibody; enlimomab; Fas ligand; glutamate receptor antagonist; infliximab; intercellular adhesion molecule 1; intercellular adhesion molecule 1 antibody; interleukin 8; interleukin 8 antibody; L selectin; l selectin antibody; monoclonal antibody; myelin associated glycoprotein; n methyl dextro aspartic acid receptor; neutralizing antibody; Nogo 66 receptor; Nogo A antibody; oligodendrocyte myelin glycoprotein; PADGEM protein; protein antibody; protein Nogo A; recombinant plasminogen activator; tissue plasminogen activator; unclassified drug; active immunization; acute kidney failure; anaphylaxis; aseptic meningitis; blood brain barrier; brain damage; brain edema; brain hemorrhage; brain ischemia; cell infiltration; cerebrovascular accident; Crohn disease; deterioration; diarrhea; dyspnea; fatigue; fever; headache; heart arrest; heart infarction; heart palpitation; hoarseness; human; immunotherapy; leukocyte function; lung edema; lung embolism; malaise; meningitis; middle cerebral artery occlusion; nausea; nerve cell plasticity; passive immunization; pneumonia; priority journal; protein subunit; review; rheumatoid arthritis; side effect; spinal cord injury; stroke related deterioration; tissue injury; treatment failure; vein thrombosis; Antibody; Immunotherapy; Stroke; Animals; Antibodies; Biomedical Research; Cell Adhesion Molecules; Cytokines; Humans; Immunologic Factors; Myelin Proteins; Neuroprotective Agents
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181806
• Institution: National University of Singapore

10.1007/s12975-013-0281-2